Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Adenosine A2B Antagonists may have potential to treat asthma and other chronic lung disease studies have found.
Sabby keeping this ticker alive for a very good reason. Short time maturity date of july 16, 2020.. whats that about?
Hooray!.. for honesty in auditing! If your right you would think that the 60+ million spent to obtain the assets (patents) or a portion of that cost would be OK to report as an asset! Looks like NSPX is just being forthright with their statements!
Ha! You know accountants/auditors dislike overstating value of intangible assets until or when their value is recognized. If or when or if ever the patents gain value by a future event the designation on the balance sheet will change from intangible to tangible with a corresponding value attached!
All your questions and concerns are valid and all will be answered in due time..patience!
Current positive information will soon be posted on newly rejuvenated website and twitter, so stay tuned for this exciting news!
Brave souls loading cheapies everyday!
Gobs of low priced shares bought today..maybe a bounce rally off the dbl bottom on the way?
You are correct the R/S has not been investor friendly and they by approval of the board can raise AS at any time, but to think that as long as there are buyers for this ticker there will be a stop in selling the stock is ludicrous!
Your research and reports concerning NSPX are not only informative but also give credence that all the IP relating to mipsagargin is not sitting in some lab somewhere collecting dust. The only true variable on the path of NSPX is time. Drug research that leads to value can be an agonizing wait and financial bust for investors especially investors that have a get rich quick pipe dream.The financial cemetery is full of investors betting on the cure for cancer!
Consultants FLG Partners and Chris Lowe as CEO took over Genspera in March 2016. They left in July 2019. The challenge is to list the 5 notable achievements of their tenure at NSPX. Authorizing 2 R/S, changing the name and shutting down operations in March 2018 don't count!
They received money from Sabby to the tune of $500,000.00 plus but instead of advancing the drug platforms Lowe used the cash to pay off his and FLG Partners Consulting Fees! Not Cool. Most Consultants have one agenda..their own!
Thus the core difference in thinking.. the thinking that Sabby is in this just to get "paid back" for the money they threw at GNSP/NSPX or is Sabby in the stock to actually make money on the years of financial support! Even if they sold out the entire a/s at these prices they wouldn't have enough money to meet the liabilities. Makes you wonder why they didn't opt for the 500:1 r/s to get more shares to discount! Lots of opinions (mostly valid) on both sides but it remains that this stock is still a crap shoot!
Sorry, I didn't now that you were privy to the internal reason why SABBY makes decisions concerning their portfolio! My BAD! March 31 is on the horizon so we will stay tuned to see what happens. If you have other inside information on why or what Sabbys next move is please post!
Hedge Fund are notorious in investing in failing or distressed companies or companies that have totally lost favor by way of debentures and or bonds. These investments are made with a large discount to the companies actual worth with the anticipation of future events vaulting the value of the company ergo the profit of the hedge fund. This may be toxic to some who don't have the resources of hedge funds but are common to the industry. This may not be the case for NSPX but it may also be possible! Getting thru all the MBA language and investment jargon of the debentures they are simply another vehicle to buy real low and sell high!
When you don't worry about money it's easy to take a position that you think may come to fruition and sit on it for a while. The anxiety of making or losing money leads to hasty decisions. The penny world is full of manipulation, pumping, bashing, reverse splits and many more losing trades than winning ones. Although many claim to be..no one is an expert! All I can say is do what you feel is right.
you are correct it may be a bust and nspx doesn't get a penny then again it may be a home run. Dr Colin Hislop seems to know his way around the bio world. I certainly don't know for sure what will go down and you or any of the other posters here don't know either!
SEC 10-Q for period 9/30/19 (most recent) on page 16 under recent developments. Aug 3, 2018 Nspx entered an agreement with Ridgeway for cancer investigation. When this first hit the business wire in Sept 2018 it was noted that NSPX may be eligible for up to 12 Million in success based milestones. I have seen nothing that says that this research has ended or that NSPX or Ridgeway has terminated this agreement. If you have please post!
Your are correct, Lowe pulled the plug on NSPX in march 2018. Shut down operations, sent the employees to the house, no phones, no website, no office no revenues, no money and no nothing. Yet Hal Mintz out of the kindness of his heart three months later lend NSPX another $500,000.00 just because it is the right thing to do!
Make some of your loss back..buy as much as you can in the 30'S and hold on for awhile these starts and stops will eventually move on to starts and gos!!
I won't be around for a few days..don't fret I haven't given up on NSPX. Just trading my computer in for something more valuable..my golf clubs! Keep up the information conversations on this ticker!
The algorithmic mathematical models that are used depend on complex relationships that are derived from trade orders, buy or sell volume, % up or down positions and other factors.. they may not be human but they react to sentiment of investors either bullish or bearish. I would say the reaction since the R/S has been bearish while in a sharp turn their reaction would be bullish! EOM
Your could be right .. MMs trying but looks like there is nothing below 4
Don't feel too bad about your loss on this stock! For solace a lot are in your same situation. Remember there has been 60 million spent since 2003 on developing the drug platforms and at present the market cap is only 40K. This is not uncommon for early stage clinical bios. You may be 100% right in trashing the stock and being disgruntled about your loss but this is an opinion board and others may have different opinions on where the ticker is headed.
Obviously picking tops and bottoms in any stock can be a trying game but a case can be made that MMs have been trashing this stock down since the R/S. The dynamic between investors who feel NSPX is on the verge of greatness and who feel NSPX is going nowhere has made fertile ground for MMs to bid this stock down. This has been going on for awhile and probably won't change until some VIABLE news come out on the company!
148.. you are correct I have no idea where Hal got the cash to buy his 10 million condo. Also, I have no idea if Sabby or any other investor will eventually make a dime on NSPX. What I do know is that Sabby has been a successful hedge fund (do the research) and they don't like to lose money on their positions. (but possible)!
Hedge Fund Boss buys 10 million Fishers Island Florida Condo..guess who! some guys really know how to make $$$$. Must be buy low sell high actually works!
I respect all your thoughts on this stock..you've been right on most recently but for Sabby to profit on just the 500k they stuck into NSPX in July 19, not taking into consideration all the other cash Sabby thru at Genspera and Inspyr over the years,the PPS of their 4+ million share position would have to climb substantially.
Good point! why would Sabby or anyone for that fact want a butt load of this cheap stock?
You are totally correct.. NSPX shut the doors, turned off the lights, packed up their bags and left the scene in March 2018. Why would Sabby or anyone for that fact loan (debenture is a loan) a company so sorry $500,000.00 plus cash?
Good question.. IMO I would say that the down trend started in 2015 when the former CEO Craig Dionne (a tremendous lab research PHD) starting to over promise the drug path by starting too many clinical trials that could not be filled by patients (for one reason or another) resulting in missed trial dates. His over promising and under performing was his demise. The board instead of replacing him with a season biotech CEO they opted to go the consulting route and hired FLG Partners. Chris Lowe was hired as ceo. This is strictly my opinion but his leadership or lack of just exasperated the downtrend. He got away from the core drug mipsagargin and thru the merger with L&C moved on to a total different drug platform. Under his leadership he changed the name and went dark for 2 1/2 years. The PPS speaks for his performance not me. So now they have two unproven drug platforms and little or no money to move forward. As now there has always been interest in both drug platforms but no solid study reports to spur big investor of big pharma interest. At the present there seems to be growing interest in both drug platforms and with Python getting patent on commercial thapsigargin interest in mipsagargin may increase. I don't feel there is a chance of them going out of business (I could be wrong) with the backing they have and IP, Patents they hold. I would say the current O/S is probably between 25 and 35 million with all the volume that has recently taken place. They need at least 60 million to break even and with the recent uptick in interest in the drug platforms, moving forward $1.00 is not out of the question and 3-5 if the right pharma wants to take a shot on both platforms. IMO
No problem.. your research and DD is SPOT on..keep it up so investors can know what they are taking a shot on!!
Great post on the Ph II study.. the first 5 words of the conclusion speaks mountains for the drug.."Mipsagargin is relatively well tolerated"...anyone who has been been treated or had family and friends treated with high power chemos knows the total loss of quality of life that most chemos entail. It has been proven that mipsagargin (thapsigargin based) is up to 10 times stronger than conventional chemo with little and/or tolerable side effects.
I always believed that Ms Thom was a good choice for the board. Her work at Takeda (Japan based and worldwide) would open doors for NSPX because the high instance of liver cancers in Asia. Craig Dionne (former Genspera CEO) also thought that mipsagargin would have a fertile market for the drug once the trials proved its worth.
8-K 8/06/19..Lowe resigns 7/15/19.. 7/26/19 The COMPANY appoints Michael Cain (not the actor) as interim CEO,CFO,President and Board member on a at will basis. The COMPANY is not party to any employment agreement or contract related to Mr Cain's employment and he will not receive any compensation at this time. (I wonder who is)
So a 35 year old IT guy is now Head Honcho of an Integrated Bio Company with a drove of IP and patents formed by the merging of Inspyr and Lewis and Clark with only 1 employee and he is working pro bono. Does this sound right or does it sound like some other entity is behind the curtain pulling the strings of this COMPANY? Could that other entity be the financial sugar daddy. All my conjecture on conspiracy theories this Sunday morning.
Nice post.. another thought on Sabby.. In 2017 Inspyr merges with L&C. Both have no revenues to speak of but form this integrated bio company. At the time both are spewing red ink! Within 8 months Lowe turns the lights out of both companies stating "lack of capital" sends everyone home, stops all activities and reduces the work force to 1 employee...himself. 3 months later he gets 500,000 from Sabby not to regenerate the operations but to keep current and pay old bills. Sabby continues thru 2018 and 2019 to fund nspx in various ways. July 2019 Lowe leaves and an interim CEO with IT background takes over (figure head?). Does it seem that Sabby cares less about operating this company but has a keen interest in keeping this company alive until such time that he can broker the IP and patents? IMO Sabby is going to breathe enough air into this company until such time he can get whole and then some!
SEC Form 8-K Dated 7/5/2015.. Sabby makes 2,500,000 investment in Genspera now Inspyr. Has supported this company since!
Zanias..you are so correct! Sabby has been keeping this company afloat since the Genspera days (long before Lowe changed the name). If and when money was needed Sabby was there with wallet open. Lowe never needed to look for financing all he needed to do was pick up the phone and call Uncle Hal Mintz. We need 500K no problem.. we another 124K.. no problem..this has been going on for years. Hard to see how Hal can afford that 10 mil condo with with all those poor financial moves!
The actual DD on Chris Lowe is that he folds up tent in march 2018 but in july gets 500,000 from sabby to "stay current and pay outstanding invoices" (most likely consultant fees from FLG Partners). On July 19 2019 gets another 154,000 from sabby for the same reason. Finally on July 26 Chris Lowe resigns and nspx and FLG part ways.. paid in full? That's all in the past..the IP is there, the patents are real, the investigations are on going, the need for more promising drugs is real, nspx has the backing of a real player so anything can happen.
Chris Lowe (former CEO) and his FLG Partners consulting firm did nothing, zilch, nada to advance the viability of NSPX. FLG's motto "We Solve Your Companies Biggest Problems" didn't exactly ring true in their tenure (march 2016 thru July 2019). The only notable things Chris Lowe did was change the name from Genspera to Inspyr, institute 2 reverse splits, shut operations down because he ran the company out of cash and after saying how transparent he would be .. he went dark for 2 1/2 years. Way to go Chris!